ELDN (Eledon Pharmaceuticals) Short Interest


ELDN Eledon Pharmaceuticals Inc ELDN
21 GF Score
Price $3.97
! 2 Warning Signs
View Full Analysis

What is Eledon Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ELDN vs ARMP, HUMA, ZNTL: Short Interest Comparison

For the Biotechnology subindustry, Eledon Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eledon Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's Short Interest falls into.


ELDN
21GF Score
Eledon Pharmaceuticals Inc ELDN
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eledon Pharmaceuticals Business Description

Other Exchanges 2TK:Germany
Address 19800 MacArthur Boulevard, Suite 250, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
21GF Score

Get the complete analysis for ELDN

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.97
Price